JP2010512414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010512414A5 JP2010512414A5 JP2009541511A JP2009541511A JP2010512414A5 JP 2010512414 A5 JP2010512414 A5 JP 2010512414A5 JP 2009541511 A JP2009541511 A JP 2009541511A JP 2009541511 A JP2009541511 A JP 2009541511A JP 2010512414 A5 JP2010512414 A5 JP 2010512414A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administered
- subject
- baseline
- ambrisentan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 claims 8
- 229960002414 ambrisentan Drugs 0.000 claims 8
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 6
- 230000007423 decrease Effects 0.000 claims 5
- 208000002815 pulmonary hypertension Diseases 0.000 claims 4
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 claims 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 1
- 230000004872 arterial blood pressure Effects 0.000 claims 1
- 230000000386 athletic effect Effects 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 239000000701 coagulant Substances 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000002250 eicosanoid group Chemical group 0.000 claims 1
- 230000000004 hemodynamic effect Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229940127293 prostanoid Drugs 0.000 claims 1
- 210000001147 pulmonary artery Anatomy 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
Claims (20)
- 療法上の有効量の組成物を対象に投与することにより対象における肺高血圧状態を処置する際に使用するための組成物であって、組成物がアンブリセンタンを含み、ベースラインにおいて、対象における状態の最初の診断からの時間が約2年よりも長くない組成物。
- 請求項1の組成物であって、肺高血圧状態が肺動脈高血圧(PAH)を含む組成物。
- 請求項2の組成物であって、PAHが特発性PAH、家族性PAHまたは他の疾患もしくは状態と関係があるPAHを含む組成物。
- 請求項2の組成物であって、PAHがベースラインにおいて少なくともWHOクラスIIのものである組成物。
- 請求項1の組成物であって、ベースラインにおいて、対象における状態の最初の診断からの時間が約0.5年よりも長くない組成物。
- 請求項1の組成物であって、対象へ投与すると、対象が次のことの少なくとも1種類を経験する組成物:
(a)ベースラインに対してより正常なレベルへ向けた、肺高血圧状態の向上を示す1種類以上の血流力学的なパラメーターの調整;
(b)ベースラインに対する運動能力の増大;
(c)ベースラインに対するBorg呼吸困難指数(BDI)の低下;
(d)ベースラインに対する1個以上の生活の質パラメーターの向上;および/または
(e)より低いWHO機能クラスへの移行。 - 請求項6の組成物であって、対象へ投与すると、平均肺動脈圧(PAP)がベースラインに対して少なくとも約3mmHg低下する組成物。
- 請求項6の組成物であって、対象へ投与すると、平均PAPがベースラインに対して少なくとも約5mmHg低下する組成物。
- 請求項6の組成物であって、対象へ投与すると、運動能力が増大し、これが6分間歩行距離(6MWD)における少なくとも約10mの増加により測定される組成物。
- 請求項6の組成物であって、対象へ投与すると、運動能力が増大し、これが6MWDにおける少なくとも約20mの増加により測定される組成物。
- 請求項6の組成物であって、対象へ投与すると、BDIがベースラインに対して少なくとも約0.5指数ポイント低下する組成物。
- 請求項6の組成物であって、対象へ投与すると、BDIがベースラインに対して少なくとも約1指数ポイント低下する組成物。
- 請求項1の組成物であって、アンブリセンタンが1日1回経口投与される組成物。
- 請求項13の組成物であって、アンブリセンタンが約1mg〜約25mgの1日投与量で投与される組成物。
- 請求項13の組成物であって、アンブリセンタンが約2.5mg〜約10mgの1日投与量で投与される組成物。
- 請求項1の組成物であって、アンブリセンタンが少なくとも約1ヶ月の処置期間の間投与される組成物。
- 請求項16の組成物であって、処置期間が少なくとも約3ヶ月である組成物。
- 請求項1の組成物であって、アンブリセンタンが単剤療法で投与される組成物。
- 請求項1の組成物であって、アンブリセンタンが肺高血圧状態またはそれと関連する状態の処置に有効な2番目の有効薬剤とともに組み合わせ療法で投与される組成物。
- 請求項19の組成物であって、2番目の有効薬剤がプロスタノイド、ホスホジエステラーゼ−5(PDE5)阻害剤、アンブリセンタン以外のエンドセリン受容体拮抗薬(ERA)、カルシウムチャンネル遮断薬、利尿薬、抗凝血剤、酸素およびそれらの組み合わせからなるグループから選択される少なくとも1種類の薬物を含む組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86966706P | 2006-12-12 | 2006-12-12 | |
PCT/US2007/087058 WO2008073928A1 (en) | 2006-12-12 | 2007-12-11 | Composition for treating a pulmonary hypertension |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010512414A JP2010512414A (ja) | 2010-04-22 |
JP2010512414A5 true JP2010512414A5 (ja) | 2011-02-03 |
Family
ID=39092031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009541511A Withdrawn JP2010512414A (ja) | 2006-12-12 | 2007-12-11 | 肺高血圧を処置するための組成物 |
Country Status (15)
Country | Link |
---|---|
US (7) | US20080139593A1 (ja) |
EP (2) | EP2952193A1 (ja) |
JP (1) | JP2010512414A (ja) |
AU (1) | AU2007333115B2 (ja) |
CA (1) | CA2669536C (ja) |
CY (1) | CY2016017I2 (ja) |
DK (1) | DK2101777T3 (ja) |
ES (1) | ES2544724T3 (ja) |
HK (1) | HK1218393A1 (ja) |
HU (2) | HUE025355T2 (ja) |
LU (1) | LU93081I2 (ja) |
PL (1) | PL2101777T3 (ja) |
PT (1) | PT2101777E (ja) |
SI (1) | SI2101777T1 (ja) |
WO (1) | WO2008073928A1 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE025355T2 (en) * | 2006-12-12 | 2016-02-29 | Gilead Sciences Inc | Composition for treating pulmonary hypertension |
US7875622B2 (en) | 2007-07-11 | 2011-01-25 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
EP2183223A2 (en) * | 2007-07-31 | 2010-05-12 | Gilead Colorado, Inc. | Metabolites and derivatives of ambrisentan |
WO2010062640A1 (en) * | 2008-10-28 | 2010-06-03 | Gilead Colorado, Inc. | Methods for treating idiopathic pulmonary fibrosis and associated complications |
CA2802891A1 (en) * | 2010-06-30 | 2012-01-05 | Gilead Sciences, Inc. | Use of a2b adenosine receptor antagonists for treating pulmonary hypertension |
NZ610012A (en) * | 2010-10-15 | 2015-05-29 | Gilead Sciences Inc | Compositions and methods of treating pulmonary hypertension |
US20140271680A1 (en) * | 2011-08-12 | 2014-09-18 | Universite Paris-Est Creteil Val De Marne | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
WO2013130119A1 (en) * | 2012-02-29 | 2013-09-06 | Gilead Sciences, Inc. | Method for treating a pulmonary hypertension condition without companion diagnosis |
US20130225595A1 (en) * | 2012-02-29 | 2013-08-29 | Gilead Sciences, Inc. | Method for treating pulmonary arterial hypertension in a patient not having idiopathic pulmonary fibrosis |
WO2014003678A1 (en) * | 2012-06-28 | 2014-01-03 | Xspray Microparticles Ab | Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil |
WO2015193889A1 (en) * | 2014-06-18 | 2015-12-23 | Sonivie Ltd. | Method for treating secondary pulmonary hypertension |
US10576083B2 (en) * | 2015-08-13 | 2020-03-03 | Cipla (UK) Limited | Method of treating pulmonary arterial hypertension |
JP2020532521A (ja) * | 2017-08-30 | 2020-11-12 | ベレロフォン パルス テクノロジーズ エルエルシー | 右室及び/又は左室機能の改善のための吸入用一酸化窒素の使用 |
KR20200127157A (ko) * | 2017-12-28 | 2020-11-10 | 벨레로폰 펄스 테크놀로지스 엘엘씨 | 폐고혈압의 치료를 위한 흡입 산화질소 및 산소의 사용 |
US20220331313A1 (en) * | 2019-05-06 | 2022-10-20 | Actelion Pharmaceuticals Ltd | Methods for treating sarcoidosis-associated pulmonary hypertension |
CA3161960A1 (en) | 2019-12-16 | 2021-06-24 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef) |
RU2729033C1 (ru) * | 2020-02-03 | 2020-08-03 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) | Способ прогнозирования эффективности длительной специфической терапии у пациентов с идиопатической легочной гипертензией и неоперабельной хронической тромбоэмболической легочной гипертензией |
EP3906928A1 (en) * | 2020-05-06 | 2021-11-10 | Noorik Biopharmaceuticals AG | Treatment of pulmonary complications of coronavirus |
EP4142731A1 (en) * | 2020-04-28 | 2023-03-08 | Noorik Biopharmaceuticals AG | Treatment of pulmonary complications of coronavirus infections |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4325525A (en) | 1980-11-13 | 1982-04-20 | General Motors Corporation | Mounting member |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
DE4313412A1 (de) | 1993-04-23 | 1994-10-27 | Basf Ag | 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung |
GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
DE19881732D2 (de) | 1997-11-12 | 2000-08-24 | Bayer Ag | 2-Phenyl-substituierte Imidazotriazinone als Phoshodiesterase Inhibitoren |
US6821975B1 (en) | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
CA2572179A1 (en) * | 2004-06-23 | 2006-01-19 | Myogen, Inc. | Enoximone formulations and their use in the treatment of pde-iii mediated diseases |
CN101072564A (zh) | 2004-08-26 | 2007-11-14 | 恩希赛弗制药公司 | 内皮缩血管肽a受体(eta)拮抗剂与磷酸二酯酶5(pde5)抑制剂的联合及其用途 |
US20060205733A1 (en) | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
WO2006081289A2 (en) | 2005-01-25 | 2006-08-03 | Glaxo Group Limited | Antibacterial agents |
BRPI0710658A2 (pt) * | 2006-04-21 | 2011-08-16 | Pfizer Prod Inc | compostos de piridina[3,4-b] pirazinonas, seus usos na preparação de composições farmacêuticas e composições farmacêuticas compreendendo os mesmos |
WO2008073927A1 (en) * | 2006-12-12 | 2008-06-19 | Gilead Colorado, Inc. | Ambrisentan combined with a renin inhibitor for hypertensive disorder |
HUE025355T2 (en) | 2006-12-12 | 2016-02-29 | Gilead Sciences Inc | Composition for treating pulmonary hypertension |
EP2183223A2 (en) | 2007-07-31 | 2010-05-12 | Gilead Colorado, Inc. | Metabolites and derivatives of ambrisentan |
WO2010062640A1 (en) | 2008-10-28 | 2010-06-03 | Gilead Colorado, Inc. | Methods for treating idiopathic pulmonary fibrosis and associated complications |
NZ610012A (en) | 2010-10-15 | 2015-05-29 | Gilead Sciences Inc | Compositions and methods of treating pulmonary hypertension |
-
2007
- 2007-12-11 HU HUE07855065A patent/HUE025355T2/en unknown
- 2007-12-11 EP EP15168201.0A patent/EP2952193A1/en not_active Withdrawn
- 2007-12-11 CA CA2669536A patent/CA2669536C/en active Active
- 2007-12-11 DK DK07855065.4T patent/DK2101777T3/en active
- 2007-12-11 PT PT78550654T patent/PT2101777E/pt unknown
- 2007-12-11 AU AU2007333115A patent/AU2007333115B2/en active Active
- 2007-12-11 EP EP07855065.4A patent/EP2101777B1/en not_active Revoked
- 2007-12-11 PL PL07855065T patent/PL2101777T3/pl unknown
- 2007-12-11 WO PCT/US2007/087058 patent/WO2008073928A1/en active Application Filing
- 2007-12-11 US US11/953,955 patent/US20080139593A1/en not_active Abandoned
- 2007-12-11 SI SI200731668T patent/SI2101777T1/sl unknown
- 2007-12-11 JP JP2009541511A patent/JP2010512414A/ja not_active Withdrawn
- 2007-12-11 ES ES07855065.4T patent/ES2544724T3/es active Active
-
2010
- 2010-02-17 US US12/706,818 patent/US20100152217A1/en not_active Abandoned
-
2011
- 2011-06-16 US US13/162,137 patent/US8377933B2/en active Active
-
2012
- 2012-12-21 US US13/723,758 patent/US20130116257A1/en not_active Abandoned
-
2014
- 2014-02-17 US US14/182,208 patent/US9474752B2/en active Active
-
2015
- 2015-04-24 US US14/695,775 patent/US9504685B2/en active Active
-
2016
- 2016-05-20 CY CY2016017C patent/CY2016017I2/el unknown
- 2016-05-20 HU HUS1600027C patent/HUS1600027I1/hu unknown
- 2016-05-20 LU LU93081C patent/LU93081I2/fr unknown
- 2016-06-06 HK HK16106422.7A patent/HK1218393A1/zh unknown
- 2016-11-23 US US15/360,304 patent/US9993475B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010512414A5 (ja) | ||
AU2013299625B2 (en) | Treatment of immune-related and inflammatory diseases | |
Eguchi et al. | Comparison of candesartan with lisinopril on ambulatory blood pressure and morning surge in patients with systemic hypertension | |
WO2006059108A3 (en) | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES | |
WO2004017896A3 (en) | Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist | |
JP2009518415A5 (ja) | ||
JP2011515349A5 (ja) | ||
Wang et al. | The role of aldosterone in OSA and OSA-related hypertension | |
CA3053991A1 (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
RU2012110592A (ru) | Соединения и способ снижения мочевой кислоты | |
Kloner et al. | Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension | |
Balakumar et al. | Cardiovascular drugs-induced oral toxicities: A murky area to be revisited and illuminated | |
JP2013528649A5 (ja) | ||
Brunner | Clinical efficacy and tolerability of olmesartan | |
JP2018502126A5 (ja) | ||
Destro et al. | Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring | |
AU2006311574A1 (en) | Use of cicletanine and other furopyridines for treatment of hypertension | |
Spinar et al. | Anti-hypertensive strategies in patients with MEtabolic parameters, DIabetes mellitus and/or NephropAthy (the MEDINA study) | |
Smith | Strategies to meet lower blood pressure goals with a new standard in angiotensin II receptor blockade | |
Lacourcière et al. | Antihypertensive effects of amlodipine and hydrochlorothiazide in elderly patients with ambulatory hypertension | |
JP4702054B2 (ja) | 増強剤 | |
AU2015305430A1 (en) | Method for treating hyperhidrosis | |
Fedecostante et al. | PP. 21.20: Hypertensive urgency and proteinuria with acute deterioration of renal function following intravitreal injection of aflibercept | |
Yatsyshyn et al. | TELMISARTAN IMPROVES ENDOTHELIAL FUNCTION IN SCLERODERMA PATIENTS WITH PULMONARY HYPERTENSION: PP. 33.335 | |
Wang et al. | P-364: AT1 receptors and hypertension in human GRK4 gamma A142V transgenic mice |